论文部分内容阅读
目的探讨RASSF1A基因启动子区异常甲基化与卵巢上皮性恶性肿瘤发生、发展的关系。方法应用甲基化特异性PCR方法,检测80例卵巢上皮性恶性肿瘤组织RASSF1A基因启动子区异常甲基化。结果80例卵巢上皮性恶性肿瘤组织中,RASSF1A基因启动子区甲基化的发生率为52.5%,而相应癌旁正常组织中,RASSF1A基因启动子区均未发生甲基化(P<0.05)。浆液性癌、黏液性癌和内膜样癌中,RASSF1A基因启动子区甲基化的发生率分别为54.2%、52.4%和45.5%,差异无统计学意义。临床Ⅰ期、Ⅱ期卵巢上皮性恶性肿瘤RASSF1A基因启动子区甲基化的发生率分别为21.4%和16.7%,明显低于临床Ⅲ期(66.7%)和Ⅳ期(77.8%)。高分化组和中分化组RASSF1A基因启动子区甲基化的发生率分别为34.5%和35.0%,均低于低分化组(80.6%)。结论卵巢上皮性恶性肿瘤组织中存在RASSF1A基因启动子区的异常甲基化,甲基化与卵巢上皮性恶性肿瘤的临床分期和组织学分级有关。
Objective To investigate the relationship between abnormal methylation of RASSF1A promoter and occurrence and development of epithelial ovarian cancer. Methods Methylation-specific PCR was used to detect the abnormal methylation of RASSF1A promoter in 80 cases of ovarian epithelial malignant tumors. Results The methylation of RASSF1A promoter was found in 80 cases of ovarian epithelial malignant tumors (52.5%). However, no methylation was found in the promoter region of RASSF1A (P <0.05) . In serous, mucinous and endometrioid carcinomas, the methylation rates of RASSF1A promoter were 54.2%, 52.4% and 45.5% respectively, with no significant difference. The incidences of methylation of RASSF1A promoter in stage Ⅰ and stage Ⅱ ovarian epithelial malignancies were 21.4% and 16.7%, respectively, which were significantly lower than those in stage Ⅲ (66.7%) and stage Ⅳ (77.8%). The prevalence of methylation of RASSF1A gene in well differentiated and moderately differentiated groups was 34.5% and 35.0%, respectively, which were lower than that in poorly differentiated group (80.6%). Conclusion Abnormal methylation of the promoter region of RASSF1A gene exists in ovarian epithelial malignant tumors. Methylation is associated with the clinical stage and histological grade of ovarian epithelial malignant tumor.